TRENDFINDERS- Scanning Board for Charts and Stocks

[califax]

Antisoma @ ASCO

http://www.antisoma.com/asm/media/press/pr2010/2010-05-17/

AS1413 – rapid recruitment continues in phase III trial
AS1413 is a novel chemotherapy treatment that we are testing in a large, multi-country, randomised phase III trial in patients with secondary acute myeloid leukaemia (secondary AML). The trial, known as ACCEDE, has now recruited over 75% of its target of 450 patients, putting us on course to complete enrolment this calendar year. Following collection and processing of data, we expect to announce results of the study during the first half of 2011.

There is interest from potential licensing partners for AS1413. We have decided to take a pragmatic stance to realising the value of this drug, and have therefore widened our partnering discussions to include US rights, which we had previously planned to retain. However, we will only strike a deal ahead of the phase III data if the terms are sufficiently favourable.

We believe that AS1413 could ultimately find application in a number of blood cancer settings, with potential sales running to hundreds of millions of dollars annually. A presentation at the American Association of Cancer Research (AACR) Annual Meeting during April reinforced the differentiation of AS1413 from currently available leukaemia treatments and its potential to provide unique benefits for patients. Three presentations with relevance to AS1413 will be made at the American Society of Clinical Oncology (ASCO) Annual Meeting in June; abstracts will be available on the ASCO website (www.asco.org) from 20 May.

AS1411 – phase IIb trial now underway
AS1411 is the most advanced aptamer in trials for cancer. It is now in a 90-patient phase IIb study in patients with AML. This trial follows an earlier randomised phase II trial in AML, which reported positive results at the 2009 ASCO meeting: in that study, two different doses of AS1411 in combination with cytarabine chemotherapy produced response rates of around 20%, whereas the response rate in patients receiving chemotherapy alone was 5%. Addition of AS1411 to chemotherapy was not associated with any significant additional side-effects. Headline data from the phase IIb study are expected in the first half of next year.

Recent and forthcoming conference presentations highlight the broad potential of AS1411. Non-clinical data presented at AACR in April showed activity in a model of colorectal cancer and positive findings when AS1411 was combined with a number of approved treatments for blood cancers. At the ASCO meeting we will have three presentations on AS1411, including updated findings from the first phase II clinical trial in AML and data from a phase II clinical trial in renal cancer.

##############################################################################################

London, UK, Cambridge, MA, and Washington, DC: 19 April 2010

AACR presentations highlight potential of Antisoma drugs AS1413_and_AS1411
http://www.antisoma.com/asm/media/press/pr2010/2010-04-19/


London, UK, and Cambridge, MA: 3 June 2010

Antisoma's AS1413 gains FDA Fast Track status for treatment of secondary acute myeloid leukaemia
http://www.antisoma.com/asm/media/press/pr2010/2010-06-03/



**

** Antisoma has a Level_One_American_Depositary_Receipt (ADR) Program.

www.antisoma.com/asm/ir/shareinfo/adr/

This will enable US investors in Antisoma to trade in a dollar-denominated security and is intended as a step towards a full listing of Antisoma's shares on NASDAQ.

Trading symbol: ATSMY
CUSIP number: 03718Q109
Ratio: 1 ADR : 20 Ordinary Antisoma shares